BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharma to Present CAN106 Ph1 Data @ the European Hematology Association. CAN106 being developed for PNH & complement-mediated diseases. Click here to view original post… […]
First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in the second half of 2022 MARLBOROUGH, Mass., May 12, 2022 /PRNewswire/ — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage… Click here to view original post… […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2022, and provided clinical development and operational highlights. “We continue to advance the AU-011… Click here to view original post… […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results Click here to view original post… […]
NEWTON, Mass.–(BUSINESS WIRE)–Corindus, A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today that it will showcase the CorPath GRX System, the first and only FDA-cleared and CE marked medical device for robotic-assisted coronary interventions, at EuroPCR 2022 through live cases, scientific presentations, and multiple Siemens… Click here to view original post… […]
Rapid antigen tests for diagnosing COVID-19 may be less effective for new coronavirus variants, particularly the delta variant, according to researchers at Harvard T.H. Chan School of Public Health and Beth Israel Deaconess Medical Center. Click here to view original post… […]
Copyright © 2026 Biotech Networks, LLC
